Gastrinoma Medical Services in China

Gastrinoma is a rare, neuroendocrine tumor that secretes excessive amounts of gastrin—typically arising from the duodenum (60–70%) or pancreas (20–30%), and less commonly from gastric, jejunal, or lymph node tissue. It is the principal cause of Zollinger–Ellison syndrome (ZES), characterized by profound gastric acid hypersecretion, recurrent peptic ulcer disease, gastroesophageal reflux, diarrhea, and malabsorption. Pathogenically, gastrinomas originate from enterochromaffin-like (ECL) cells or gastrin-producing G-cells in the antrum or duodenal Brunner’s glands. Most sporadic cases involve somatic mutations in genes such as MEN1, CDKN1B, or DAXX/ATRX; approximately 20–25% occur in the context of multiple endocrine neoplasia type 1 (MEN1), an autosomal dominant disorder with germline MEN1 gene mutations. Tumor behavior varies: while ~60–70% are malignant at diagnosis (with hepatic or lymph node metastases), duodenal tumors tend to be smaller and less aggressive than pancreatic ones. Epidemiologically, gastrinoma incidence is estimated at 0.5–2 cases per million person-years, with a median age at diagnosis of 50–60 years and slight male predominance (M:F ≈ 1.5:1). Risk factors include familial MEN1 syndrome, prior gastric surgery (e.g., vagotomy), chronic atrophic gastritis, and possibly long-standing proton pump inhibitor (PPI) use—though causality remains unproven. Diagnosis hinges on elevated fasting serum gastrin (>1000 pg/mL), gastric acid hypersecretion (basal acid output >15 mEq/h), and provocative testing (e.g., secretin stimulation test); imaging (EUS, SRS, Ga-68 DOTATATE PET/CT) localizes tumors. Untreated, gastrinoma significantly impairs quality of life: chronic abdominal pain, debilitating diarrhea, weight loss, nutritional deficiencies (e.g., iron, B12, calcium), fatigue, and anxiety related to recurrent ulcers or cancer progression are common. Even with treatment, lifelong PPI therapy is often required, and patients face surveillance burdens, surgical morbidity, and psychosocial stress—including concerns about malignancy, hereditary risk for family members, and limitations in diet, travel, and work due to GI instability. Early detection and multidisciplinary management (endocrinology, gastroenterology, oncology, surgery) markedly improve outcomes and functional status.

Gastrinoma is a rare, usually malignant neuroendocrine tumor (NET) that secretes excessive amounts of gastrin, leading to Zollinger–Ellison syndrome (ZES). It most commonly arises in the duodenum (approximately 60–70% of cases) or pancreas (20–30%), with occasional ectopic origins in the stomach, lymph nodes, ovary, or liver. The primary cause is somatic or germline mutations driving uncontrolled proliferation and hormone hypersecretion in gastrin-producing enterochromaffin-like (ECL) cells or, more frequently, in non-beta pancreatic islet cells or duodenal G-cells. While the precise initiating event remains incompletely elucidated, dysregulation of key signaling pathways—including MEN1, CDKN1B, DAXX/ATRX, and mTOR—is consistently implicated.

Genetic factors play a pivotal role: approximately 25–30% of gastrinomas occur in the context of multiple endocrine neoplasia type 1 (MEN1), an autosomal dominant disorder caused by inactivating germline mutations in the MEN1 tumor suppressor gene on chromosome 11q13. MEN1-associated gastrinomas are typically multifocal, smaller, less aggressive, and often diagnosed earlier than sporadic cases. Rarely, gastrinomas may arise in association with von Hippel–Lindau (VHL) disease or neurofibromatosis type 1 (NF1), though these associations are far less common and mechanistically less defined. Germline CDKN1B mutations (causing MEN4) have also been reported in isolated cases of ZES, underscoring the importance of genetic counseling and cascade testing for first-degree relatives when a hereditary syndrome is suspected.

Sporadic gastrinomas—accounting for ~70% of cases—are driven predominantly by acquired (somatic) genetic alterations. Recurrent somatic mutations include MEN1 (in >40% of sporadic tumors), DAXX (30–40%), ATRX (20–30%), and mTOR pathway components (e.g., TSC2, PTEN). Chromosomal losses at 1p, 3p, 6q, 10q, 11q (including MEN1 locus), and 22q are frequent; gains at 4p, 5p, 7p, 9q, 12q, 14q, 17q, and 20q are also observed. Epigenetic dysregulation—including aberrant DNA methylation and histone modification—further contributes to tumorigenesis and hormone dyssecretion.

Environmental and modifiable risk factors are not well established, as gastrinoma lacks strong epidemiologic associations with lifestyle exposures such as smoking, alcohol use, diet, or occupational toxins. However, chronic gastric acid suppression—particularly long-term, high-dose proton pump inhibitor (PPI) therapy—may unmask or exacerbate underlying gastrinoma by inducing profound hypergastrinemia, which can theoretically promote ECL-cell hyperplasia and, rarely, progression to neoplasia in predisposed individuals. Importantly, PPIs do not cause gastrinoma but may delay diagnosis by masking ulcer symptoms or mimicking functional dyspepsia. Prior gastric surgery (e.g., vagotomy or antrectomy) historically conferred elevated gastrin levels due to loss of inhibitory feedback, but this is now largely obsolete and not considered a current risk factor.

Triggers for clinical presentation are primarily physiological and biochemical: fasting serum gastrin >1000 pg/mL (especially with gastric pH <2), provocative testing abnormalities (e.g., exaggerated gastrin response to secretin or calcium infusion), and evidence of gastric acid hypersecretion (basal acid output >15 mEq/h). Acute gastrointestinal stressors—including severe illness, renal failure, or acute atrophic gastritis—can transiently elevate gastrin and complicate interpretation. Concurrent use of PPIs or H2-receptor antagonists is the most common confounder in diagnostic evaluation and must be withdrawn for ≥1 week (preferably 2 weeks) prior to testing. Other triggers of symptomatic exacerbation include ingestion of protein-rich meals (which physiologically stimulate gastrin release), NSAID use (exacerbating mucosal injury), and stress-induced mucosal vulnerability.

Demographic and clinical risk factors include male sex (male-to-female ratio ~2:1), age at diagnosis (peak incidence 40–60 years), and presence of recurrent or refractory peptic ulcer disease, especially with complications (hemorrhage, perforation, obstruction) or extra-duodenal ulcers. Patients with diarrhea-predominant ZES, large or metastatic tumors (>3 cm), or hepatic metastases carry worse prognoses. Duodenal gastrinomas are associated with lower metastatic potential than pancreatic primaries, whereas lymph node involvement portends higher recurrence risk. Notably, absence of MEN1 does not exclude familial clustering—some families exhibit phenocopies without identifiable MEN1 mutations, suggesting additional undiscovered susceptibility loci. In summary, gastrinoma pathogenesis reflects a convergence of inherited predisposition, somatic genomic instability, and dysregulated neuroendocrine signaling, with minimal contribution from environmental exposures. Early recognition hinges on maintaining a high index of suspicion in patients with atypical ulcer disease, unexplained diarrhea, or recurrent GERD refractory to standard therapy.

Gastrinoma is a rare, usually malignant neuroendocrine tumor that secretes excessive amounts of gastrin, most commonly arising from the duodenum (approximately 50–70%) or pancreas (20–40%), and less frequently from the stomach, lymph nodes, or ectopic locations. It is the principal cause of Zollinger–Ellison syndrome (ZES), characterized by hypergastrinemia, gastric acid hypersecretion, and recurrent peptic ulcer disease. Clinical presentation varies widely depending on tumor size, location, functional status, and presence of metastases; symptoms may be subtle and nonspecific in early stages, leading to diagnostic delays averaging 3–5 years.

Early symptoms are often insidious and easily misattributed to common gastrointestinal disorders. Patients may report intermittent epigastric discomfort, mild heartburn (pyrosis), or postprandial bloating—symptoms frequently mistaken for functional dyspepsia or gastroesophageal reflux disease (GERD). Some experience episodic diarrhea, particularly nocturnal or watery diarrhea unresponsive to conventional antidiarrheals, which reflects acid-induced mucosal injury and impaired intestinal fluid absorption. Early-stage gastrinomas may also manifest as atypical or recurrent gastric or duodenal ulcers despite standard proton pump inhibitor (PPI) therapy, or as unexplained iron-deficiency anemia due to chronic occult gastrointestinal bleeding from erosions or ulcers. Notably, up to 25% of patients present with no ulcer disease at diagnosis—highlighting that ulceration is not obligatory for ZES.

Typical symptoms emerge as gastrin-driven acid hypersecretion intensifies. Profound gastric acid hypersecretion leads to severe, refractory peptic ulcer disease: ulcers are often multiple, located distally in the duodenum (beyond the bulb) or even in the jejunum—a hallmark feature. Patients commonly describe burning epigastric pain exacerbated by fasting and relieved transiently by food or antacids—but unlike typical ulcers, pain recurs rapidly and is poorly controlled with standard antisecretory doses. Esophageal involvement is frequent, resulting in erosive esophagitis, strictures, or Barrett’s esophagus due to chronic acid reflux. Diarrhea becomes more prominent—occurring in 50–70% of cases—and is typically secretory in nature: large-volume, watery, and associated with steatorrhea due to acid-induced inactivation of pancreatic lipase and bile salt precipitation. Hypochlorhydria is absent; rather, basal acid output (BAO) is markedly elevated (>15 mEq/h, often >30 mEq/h), and maximal acid output (MAO) remains high despite PPI use.

Accompanying symptoms reflect both hormonal excess and tumor burden. Weight loss occurs in ~40% of patients, attributable to malabsorption, chronic pain, anorexia, or tumor cachexia. Fatigue and weakness may stem from chronic anemia, electrolyte disturbances (e.g., hypokalemia secondary to diarrhea), or vitamin deficiencies—particularly B12 deficiency due to achlorhydria-independent mechanisms involving altered intrinsic factor binding in acidic milieu. Approximately 25% of gastrinomas occur in the context of multiple endocrine neoplasia type 1 (MEN1), so accompanying features may include primary hyperparathyroidism (nephrolithiasis, bone pain, fatigue), pituitary adenoma (headache, amenorrhea/galactorrhea, acromegaly), or other neuroendocrine tumors (e.g., insulinoma, glucagonoma). Cutaneous manifestations such as necrolytic migratory erythema are rare but reported in association with concomitant glucagon excess.

Complications arise from prolonged acid hypersecretion and tumor progression. Gastrointestinal complications include gastrointestinal bleeding (hematemesis, melena), perforation, gastric outlet obstruction from scarring or edema, and esophageal stricture or adenocarcinoma (Barrett’s-related). Malabsorption syndromes lead to deficiencies in fat-soluble vitamins (A, D, E, K), calcium, magnesium, and zinc—potentially causing osteoporosis, coagulopathy, or neuropathy. Metastatic disease—most commonly to regional lymph nodes, liver, bone, or lung—occurs in ~60–80% of sporadic cases at diagnosis; hepatic metastases may cause right upper quadrant pain, hepatomegaly, or jaundice. Tumor-related complications include carcinoid syndrome (flushing, wheezing, diarrhea) in cases with serotonin co-secretion (rare), and Cushing’s syndrome if ectopic ACTH secretion occurs (exceptionally rare).

Diagnosis hinges on biochemical confirmation followed by localization. First-line testing is fasting serum gastrin (FSG): levels >1000 pg/mL in the presence of gastric acidity (pH <2) are highly specific for gastrinoma; however, moderate elevations (100–1000 pg/mL) require provocative testing. The gold-standard provocative test is the secretin stimulation test: intravenous secretin (2 U/kg) normally suppresses gastrin in healthy individuals and patients with peptic ulcer disease, but induces a paradoxical rise (>200 pg/mL above baseline) in >90% of gastrinoma patients. Gastric pH measurement (via nasogastric aspiration or wireless capsule) confirms acid hypersecretion (pH <2). Additional tests include serum chromogranin A (elevated in most neuroendocrine tumors, though nonspecific), and measurement of basal acid output (BAO) and BAO/MAO ratio (>0.6 suggests ZES). Localization relies on high-resolution imaging: contrast-enhanced CT or MRI of the abdomen/pelvis detects larger tumors (>2 cm); endoscopic ultrasound (EUS) offers superior sensitivity for small duodenal or pancreatic lesions (detecting >80% of tumors <1 cm); somatostatin receptor imaging (e.g., 68Ga-DOTATATE PET/CT) demonstrates high sensitivity and specificity (>95%) for primary and metastatic disease, especially in well-differentiated tumors expressing SSTR2. Selective arterial calcium stimulation with hepatic venous sampling (SACSV) may be used when imaging is negative but clinical suspicion remains high.

Differential diagnosis includes conditions mimicking hypergastrinemia or peptic ulcer disease. Functional hypergastrinemia must be excluded: chronic atrophic gastritis (with achlorhydria), long-term PPI use (rebound hypergastrinemia), renal failure (impaired gastrin clearance), and vagotomy (loss of inhibitory neural input). These typically show low or normal gastric acidity (pH >4) and lack secretin-stimulated gastrin rise. Other neuroendocrine tumors—such as VIPoma (causing WDHA syndrome: watery diarrhea, hypokalemia, achlorhydria) or medullary thyroid carcinoma (with calcitonin elevation)—must be distinguished biochemically. Non-functioning pancreatic neuroendocrine tumors do not elevate gastrin. Peptic ulcer disease from H. pylori infection or NSAID use lacks hypergastrinemia and responds to eradication or cessation. Rarely, antral G-cell hyperplasia or short-bowel syndrome may cause hypergastrinemia but without acid hypersecretion or ulcer diathesis. Accurate differentiation requires integrated assessment of gastrin levels, gastric pH, secretin response, imaging, and histopathology.

Gastrinoma is a rare, neuroendocrine tumor (NET) that secretes excessive gastrin, leading to Zollinger–Ellison syndrome (ZES). It most commonly arises in the duodenum (60–70%) or pancreas (20–30%), with occasional ectopic origins. Gastrinomas are often malignant—approximately 60–70% exhibit lymph node or hepatic metastases at diagnosis—and approximately 25% occur sporadically, while the remainder are associated with multiple endocrine neoplasia type 1 (MEN1). Management requires a multidisciplinary approach coordinated by endocrinology, gastroenterology, surgical oncology, nuclear medicine, and pathology.

Conservative treatment is indicated for patients with unresectable, metastatic, or asymptomatic disease, particularly those with indolent tumor biology or significant comorbidities precluding surgery. The cornerstone of conservative management is gastric acid suppression using high-dose proton pump inhibitors (PPIs), such as esomeprazole (40–120 mg twice daily) or pantoprazole (80–240 mg daily), titrated to maintain basal gastric pH >4 and resolve symptoms (e.g., refractory peptic ulcer disease, diarrhea, gastroesophageal reflux). PPI therapy does not inhibit tumor growth but prevents life-threatening complications including ulcer perforation, hemorrhage, and strictures. Long-term PPI use necessitates monitoring for hypomagnesemia, vitamin B12 deficiency, and potential rebound hypergastrinemia; however, elevated serum gastrin in this context reflects pharmacologic inhibition—not tumor progression—and must be interpreted cautiously. Endoscopic surveillance every 1–2 years is recommended to detect mucosal complications. In select cases with stable, low-volume liver metastases, active surveillance with serial imaging (MRI or contrast-enhanced CT) and chromogranin A/gastrin levels every 3–6 months may be appropriate.

Pharmacotherapy extends beyond acid suppression. Somatostatin analogues (SSAs)—octreotide LAR (20–30 mg intramuscularly every 4 weeks) or lanreotide Autogel (90–120 mg subcutaneously monthly)—are first-line systemic agents for symptomatic control and antiproliferative activity in well-differentiated, somatostatin receptor–positive (SSTR+) gastrinomas. SSAs reduce gastrin secretion, alleviate diarrhea, and stabilize tumor growth in ~60–70% of patients. Peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTATATE is FDA- and NMPA-approved for progressive, SSTR-positive G1/G2 NETs—including gastrinoma—and demonstrates objective response rates of 15–30%, prolonged progression-free survival (median ~28 months), and improved quality of life. For higher-grade (G3) or PRRT-ineligible tumors, cytotoxic chemotherapy (e.g., capecitabine/temozolomide) or targeted agents (everolimus, sunitinib) may be considered based on molecular profiling and tumor grade. Molecular testing—including MEN1 germline sequencing—is mandatory in all newly diagnosed patients to guide genetic counseling and screening of relatives.

Surgical resection remains the only potentially curative intervention and is strongly recommended for localized, resectable gastrinomas without distant metastases. En bloc resection with regional lymphadenectomy is standard: pancreatic head tumors require Whipple procedure; duodenal tumors necessitate segmental duodenectomy with ampullary preservation when feasible; and small, superficial duodenal lesions may be excised endoscopically or via laparoscopic wedge resection. Preoperative localization is critical and typically involves dual-phase contrast-enhanced CT/MRI, endoscopic ultrasound (EUS), and ⁶⁸Ga-DOTATATE PET/CT—which offers superior sensitivity (>90%) and specificity for primary and metastatic disease. In MEN1-associated gastrinoma, surgery is more nuanced: duodenal microgastrinomas are nearly universal, and prophylactic pancreaticoduodenectomy is not advised due to high morbidity; instead, selective resection of dominant lesions ≥1 cm with nodal sampling is preferred. Complete resection (R0) correlates with 10-year survival exceeding 90%, whereas R1/R2 resection or unresectable disease reduces 10-year survival to 40–60%.

China offers distinct advantages in gastrinoma management. First, advanced multimodal imaging—including widespread access to ⁶⁸Ga-DOTATATE PET/CT and high-resolution EUS—is increasingly available in tier-1 and tier-2 hospitals, enabling precise staging. Second, China’s National Medical Products Administration (NMPA) has expedited approvals for key therapeutics: ¹⁷⁷Lu-DOTATATE received conditional approval in 2022, and generic octreotide LAR and lanreotide are widely accessible at lower cost than in Western markets. Third, specialized NET centers—such as those at Peking Union Medical College Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—employ integrated tumor boards with standardized protocols aligned with ENETS and NANETS guidelines. Fourth, China’s large patient volume supports robust clinical trial participation, including investigator-initiated studies on novel SSA formulations and combination therapies. Finally, centralized pathology review through national NET reference networks ensures accurate grading (Ki-67 index, mitotic count) and immunohistochemical profiling (chromogranin A, synaptophysin, SSTR2), minimizing diagnostic variability.

Post-treatment recovery emphasizes long-term surveillance and lifestyle adaptation. Patients require lifelong follow-up: fasting serum gastrin, chromogranin A, and liver function tests every 3–6 months for the first 3 years, then annually if stable; abdominal MRI or CT every 6–12 months; and ⁶⁸Ga-DOTATATE PET/CT every 1–2 years for high-risk or metastatic cases. Dietary counseling should emphasize small, frequent meals; avoidance of caffeine, alcohol, and NSAIDs; and calcium/vitamin D supplementation if on chronic PPIs. Psychological support is essential—patients often experience anxiety related to cancer recurrence and chronic symptom burden. Genetic counseling is mandatory for all patients and first-degree relatives in suspected MEN1 cases. Smoking cessation is strongly advised, as tobacco use accelerates NET progression. Finally, patients should be educated to recognize red-flag symptoms—including hematemesis, melena, severe abdominal pain, or new-onset jaundice—and seek urgent evaluation. With comprehensive, individualized care spanning medical, surgical, and supportive domains, gastrinoma outcomes continue to improve globally—and China’s rapidly evolving infrastructure positions it as a leader in accessible, evidence-based NET management.